Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of post-CABG atrial fibrillation
IRCT20200328046886N9Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Occurrence of postoperative atrial fibrillation. Started May 2026; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20200328046886N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046886N9.